Serotonin Syndrome — Recognition and Treatment

Key Points

• Clonus and hyperreflexia are key diagnostic clues in a patient with serotonergic exposure.
• Onset is usually rapid, often within hours of a medication change, interaction, or overdose.
• Stop serotonergic drugs and use benzodiazepines as the main treatment for agitation and muscle activity.
• Antipyretics are ineffective for severe serotonin-related hyperthermia.
• Severe hyperthermia requires external cooling and sometimes paralysis with a nondepolarizing agent.
• Cyproheptadine is an oral or enteral adjunct, not a substitute for airway, sedation, and cooling.
• Distinguish serotonin syndrome from NMS by rapid onset, hyperreflexia, and clonus.
• Monitor for rhabdomyolysis, hyperkalemia, acidosis, renal injury, and DIC in severe cases.

Algorithm

1. Identify serotonergic exposures, recent additions or dose changes, recreational drugs, and interaction risks.
2. Assess temperature, clonus, ocular movements, reflexes, tone, agitation, diaphoresis, bowel sounds, and hemodynamics.
3. Stop serotonergic agents and provide benzodiazepine sedation, IV fluids as needed, and continuous monitoring.
4. Use active external cooling for significant hyperthermia.
5. Give cyproheptadine enterally for persistent moderate toxicity when clinically appropriate.
6. If severe hyperthermia or rigidity persists, intubate and use nondepolarizing neuromuscular blockade with critical-care support.
7. Treat complications including hyperkalemia, acidosis, rhabdomyolysis, seizure, and DIC.
8. Observe until neuromuscular and autonomic findings resolve and establish a safe medication plan before discharge.

Clinical Synopsis & Reasoning

Serotonin toxicity usually begins within hours of a new serotonergic medication, dose increase, overdose, or drug interaction. Common contributors include SSRIs, SNRIs, MAO inhibitors, linezolid, tramadol, dextromethorphan, MDMA, certain opioids, lithium, and combinations of serotonergic agents. The classic triad is mental-status change, autonomic hyperactivity, and neuromuscular abnormalities, but clonus, ocular clonus, hyperreflexia, tremor, and lower-extremity predominance are particularly discriminating.

The Hunter Serotonin Toxicity Criteria are useful when a serotonergic exposure is present. Findings such as spontaneous clonus, inducible or ocular clonus with agitation or diaphoresis, tremor with hyperreflexia, or hypertonia plus fever and clonus support the diagnosis. Severe hyperthermia results primarily from intense skeletal muscle activity rather than a hypothalamic fever set point, so antipyretics are ineffective.

Differentiate serotonin syndrome from NMS, anticholinergic toxicity, malignant hyperthermia, sympathomimetic intoxication, sepsis, meningitis, heat stroke, and withdrawal syndromes. Serotonin syndrome generally has rapid onset and prominent clonus and hyperreflexia, whereas NMS develops more slowly with lead-pipe rigidity and bradyreflexia or normal reflexes. Laboratory testing is directed at complications such as rhabdomyolysis, acidosis, renal injury, DIC, and hyperkalemia rather than confirming the diagnosis.

Treatment Strategy & Disposition

Stop all serotonergic agents immediately. Place the patient in a low-stimulation environment, give IV fluids as indicated, and treat agitation and muscle activity with benzodiazepines. Mild cases often resolve with drug withdrawal and observation. Moderate cases require continuous monitoring, repeated sedation, temperature management, and attention to autonomic instability.

For severe hyperthermia, use rapid external cooling, deep benzodiazepine sedation, and early intubation with a nondepolarizing neuromuscular blocker if muscle activity cannot be controlled. Avoid succinylcholine when severe rhabdomyolysis and hyperkalemia are possible. Antipyretics do not work because heat generation is muscular. Short-acting agents such as esmolol or nitroprusside may be used by experienced clinicians for severe hypertension or tachycardia; avoid long-acting beta blockade in an unstable toxidrome.

Cyproheptadine, an oral/enteral serotonin antagonist, can be used when supportive care and benzodiazepines are insufficient in moderate toxicity. A common regimen is 12 mg initially, followed by 2 mg every 2 hours until response, then maintenance dosing such as 8 mg every 6 hours. It cannot be given IV, so it is not the first priority in a critically unstable patient. Admit moderate or severe cases, and use ICU care for hyperthermia, rigidity, organ injury, or need for airway control.

Epidemiology / Risk Factors

• Serotonin syndrome is usually medication-related and can occur at therapeutic doses when interacting serotonergic agents are combined.
• Overdose involving MAO inhibitors or combinations of potent serotonergic drugs carries higher risk of severe toxicity.
• The increasing use of serotonergic antidepressants makes recognition relevant across emergency, primary, psychiatric, and inpatient care.
• Recreational substances such as MDMA can cause severe hyperthermia and mixed sympathomimetic-serotonergic toxicity.
• Older adults and patients with polypharmacy are at increased interaction risk.

Investigations

Cyproheptadine Dosing (Example)

Pharmacology

Prognosis / Complications

• Mild and moderate cases usually improve within 24 hours after short-acting agents are stopped and supportive care is provided.
• Long-acting drugs, active metabolites, MAO inhibitors, and sustained-release overdoses can prolong toxicity.
• Core temperature elevation above 40 C, severe acidosis, hyperkalemia, DIC, and renal failure are markers of life-threatening disease.
• Permanent neurologic injury is uncommon when hyperthermia and complications are reversed promptly.
• Recurrence is preventable when the causative interaction is identified and the medication plan is corrected.

Patient Education / Counseling

• Give the patient a written list of the suspected causative medications and interactions.
• Do not restart serotonergic medications until symptoms have fully resolved and an appropriate washout interval has been determined.
• Warn against combining prescription antidepressants with unreviewed supplements, dextromethorphan-containing products, or recreational serotonergic drugs.
• Patients should seek urgent care for recurrent agitation, tremor, clonus, fever, confusion, or severe diarrhea after a medication change.
• When psychiatric medications are stopped during treatment, arrange follow-up so the underlying mood or anxiety disorder is not left untreated.
• Intentional overdose requires mental-health assessment after medical stabilization.

Notes

Severe serotonin syndrome is primarily a hypermetabolic muscle emergency. The most effective temperature treatment is to stop muscle activity with sedation, cooling, and, when necessary, paralysis, not to give acetaminophen.

Hunter criteria perform best in the correct exposure context. Clonus without a serotonergic medication or toxin should prompt consideration of other neurologic disease rather than automatic labeling as serotonin syndrome.

References

1. American Heart Association 2025 Special Circumstances of Resuscitation — Link